Brief: Arvinas - Announces Re-Prioritization Of Portfolio Following Strategic Review - SEC Filing
02/06/2026 21:58
BRIEF-Arvinas - Announces Re-Prioritization Of Portfolio Following Strategic Review - SEC Filing June 2 (Reuters) - Arvinas Inc ARVN.O:
ARVINAS - ANNOUNCES RE-PRIORITIZATION OF PORTFOLIO FOLLOWING STRATEGIC REVIEW - SEC FILING
ARVINAS - PLANS TO COMPLETE PHASE 1 MONOTHERAPY DOSE ESCALATION TRIAL AND SHARE DATA IN 2026 - SEC FILING
ARVINAS - PLANS TO SEEK OUT-LICENSING AGREEMENT FOR ADDITIONAL CLINICAL TRIALS OF ARV-806 - SEC FILING
ARVINAS - EXPECTS CASH POSITION AS OF MARCH 31, 2026 TO FUND OPERATIONS INTO SECOND HALF OF 2028 - SEC FILING
Source text: [ID:n0001628280-26-039818]
Further company coverage: ARVN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arvinas
See all newsBrief: Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Arvinas Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Arvinas - Pfizer, And Rigel Receive Hart-Scott-Rodino Clearance For License Agreement On June 11, 2026
Brief: Arvinas - Announces Re-Prioritization Of Portfolio Following Strategic Review - SEC Filing
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology